Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced its support for the first-ever Acute Myeloid Leukemia Awareness Month to be held in June. The goal of the campaign, which is being sponsored by CancerCare, is to put a spotlight on the disease, a rare and difficult-to-treat blood cancer that typically affects older adults.
Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and can worsen quickly if left untreated. According to the National Institutes of Health, it is estimated that there will be 19,950 new cases of acute myeloid leukemia in 2016 and an estimated 10,430 people will die from the disease. AML is more common in older adults, who are also the most difficult to treat, with 67 as the median age of diagnosis. While progress in treating leukemia has been made, there has been only one AML treatment approved by the U.S. Food and Drug Administration in the past 30 years (and that drug was subsequently withdrawn from the market).
Patricia J. Goldsmith, CEO of CancerCare, said, “AML Awareness Month will feature in-depth information about AML on the organization’s website, including a video that features NBA broadcasterCraig Sager who is battling the disease, as well as his son, Craig, Jr., who donated his bone marrow twice in an effort to save his father. The website will also offer people living with AML and their caregivers easy-to-use, informative resources to understand their condition. We thank Sunesis Pharmaceuticals for their unrestricted educational grant which has helped to support the development of these resources.”
“We are delighted to be supporting CancerCare’s efforts to raise awareness of acute myeloid leukemia,” said Daniel Swisher, Chief Executive Officer of Sunesis. “Because it is a rare disease with an older patient population, there has been little attention focused on AML. As a company that is determined to deliver a new treatment option for this disease, we want to support the AML community by helping to provide more education and information for patients and caregivers.”
Goldsmith added, “The AML community’s voice has not always been heard because the disease itself is so rare and the mortality rate is so high. We hope to put a spotlight on AML in June and help focus attention on the urgent need these patients and their families have for hope.” (Original Source)
Shares of Sunesis closed yesterday at $0.479, down $0.02 or -3.23%. SNSS has a 1-year high of $3.72 and a 1-year low of $0.44. The stock’s 50-day moving average is $0.51 and its 200-day moving average is $0.71.
On the ratings front, Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating on SNSS, in a report issued on May 5. According to TipRanks.com, Goldstein has a yearly average return of -11%, a 39% success rate, and is ranked #3802 out of 3869 analysts.
Sunesis Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company primarily engages in development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The company’s primary activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital.